Abstract: The present inventors have harnessed the targeting of nanoparticles to tumor sites, combined with the tumor site specific elevated MMP-14 activity within one conjugate to simultaneously deliver a vascular disrupting agent (VDA) and a MRI contrast agent to a tumor site. The MMP activatable conjugate of the present invention provides both therapeutic and diagnostic functions—and is referred to as a “theranostic”. The theranostic conjugate of the present invention achieves the benefits of tumor site specificity, VDA delivery and MRI contrast agent delivery in a single theranostic conjugate. Consequently, the present invention provides a cancer “theranostic” which improves therapeutic efficacy while simultaneously reducing dose-limiting systemic toxicities and provides a tool for rapidly and non-invasively identifying tumor location, monitoring drug delivery and pharmacodynamics.
Type:
Grant
Filed:
July 25, 2014
Date of Patent:
February 12, 2019
Assignees:
The Trustees of The Leland Stanford Junior University, Incanthera Ltd
Inventors:
Paul Loadman, Robert Falconer, Jason Gill, Jianghong Rao, Heike E. Daldrup-Link
Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
Type:
Grant
Filed:
May 6, 2016
Date of Patent:
May 1, 2018
Assignee:
INCANTHERA LTD
Inventors:
Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
Type:
Grant
Filed:
October 19, 2016
Date of Patent:
April 10, 2018
Assignee:
Incanthera Ltd
Inventors:
Robert Andrew Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
Type:
Grant
Filed:
December 17, 2013
Date of Patent:
June 7, 2016
Assignee:
Incanthera Ltd
Inventors:
Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
Type:
Grant
Filed:
March 27, 2008
Date of Patent:
April 8, 2014
Assignee:
Incanthera Ltd
Inventors:
Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Atkinson, Mike Bibby